PepGen (PEPG) Competitors $1.43 -0.04 (-2.72%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.42 0.00 (-0.35%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PEPG vs. DRUG, IPHA, CYBN, PRQR, LYEL, VYGR, NVCT, OGI, VTYX, and ELDNShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Bright Minds Biosciences (DRUG), Innate Pharma (IPHA), Cybin (CYBN), ProQR Therapeutics (PRQR), Lyell Immunopharma (LYEL), Voyager Therapeutics (VYGR), Nuvectis Pharma (NVCT), Organigram (OGI), Ventyx Biosciences (VTYX), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. PepGen vs. Its Competitors Bright Minds Biosciences Innate Pharma Cybin ProQR Therapeutics Lyell Immunopharma Voyager Therapeutics Nuvectis Pharma Organigram Ventyx Biosciences Eledon Pharmaceuticals PepGen (NASDAQ:PEPG) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking. Does the media refer more to PEPG or DRUG? In the previous week, PepGen had 18 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 24 mentions for PepGen and 6 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.11 beat PepGen's score of 0.02 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 0 Very Positive mention(s) 2 Positive mention(s) 19 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor PEPG or DRUG? PepGen received 11 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 91.67% of users gave Bright Minds Biosciences an outperform vote while only 81.48% of users gave PepGen an outperform vote. CompanyUnderperformOutperformPepGenOutperform Votes2281.48% Underperform Votes518.52%Bright Minds BiosciencesOutperform Votes1191.67% Underperform Votes18.33% Do institutionals & insiders hold more shares of PEPG or DRUG? 58.0% of PepGen shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 5.2% of PepGen shares are held by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, PEPG or DRUG? PepGen has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -5.75, indicating that its share price is 675% less volatile than the S&P 500. Which has stronger valuation and earnings, PEPG or DRUG? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$78.63M-$3.13-0.46Bright Minds BiosciencesN/AN/A-$2.06M-$0.36-76.61 Is PEPG or DRUG more profitable? Bright Minds Biosciences' return on equity of -5.85% beat PepGen's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -60.17% -48.88% Bright Minds Biosciences N/A -5.85%-5.68% Do analysts rate PEPG or DRUG? PepGen currently has a consensus target price of $7.67, indicating a potential upside of 436.13%. Bright Minds Biosciences has a consensus target price of $83.25, indicating a potential upside of 201.85%. Given PepGen's higher probable upside, research analysts plainly believe PepGen is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryBright Minds Biosciences beats PepGen on 10 of the 16 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.79M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.15%P/E Ratio-0.488.5026.7819.65Price / SalesN/A263.11404.49152.18Price / CashN/A65.8538.2534.64Price / Book0.316.526.964.59Net Income-$78.63M$143.48M$3.23B$248.23M7 Day Performance-4.67%-0.20%-1.24%-1.07%1 Month Performance3.62%11.63%8.34%3.35%1 Year Performance-91.71%3.21%33.30%13.77% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen2.7007 of 5 stars$1.43-2.7%$7.67+436.1%-91.8%$46.79MN/A-0.4830Trending NewsGap UpDRUGBright Minds Biosciences3.3095 of 5 stars$27.88+1.0%$83.25+198.6%+2,424.5%$196.39MN/A-163.99N/APositive NewsAnalyst RevisionIPHAInnate Pharma3.1388 of 5 stars$2.12-2.5%$11.00+420.1%-20.0%$194.95M$12.62M0.00220CYBNCybin2.735 of 5 stars$8.45-5.1%$86.00+917.8%N/A$193.59MN/A-1.9350News CoveragePositive NewsAnalyst RevisionPRQRProQR Therapeutics1.9578 of 5 stars$1.83-4.2%$8.00+337.2%+5.0%$192.54M$18.97M-5.72180Positive NewsAnalyst RevisionLYELLyell Immunopharma3.1533 of 5 stars$12.47-2.3%$20.00+60.4%-81.2%$188.95M$65K-15.78270Short Interest ↓Gap DownHigh Trading VolumeVYGRVoyager Therapeutics4.4158 of 5 stars$3.35-5.4%$13.39+299.7%-62.5%$185.38M$66.96M4.72100News CoverageAnalyst RevisionGap DownNVCTNuvectis Pharma2.928 of 5 stars$8.85flat$17.00+92.1%+23.1%$184.91MN/A-7.638News CoveragePositive NewsOGIOrganigram0.6203 of 5 stars$1.38+2.2%N/A-10.3%$184.76M$194.09M-3.63860News CoveragePositive NewsVTYXVentyx Biosciences2.3937 of 5 stars$2.56+4.1%$10.00+290.6%-10.8%$182.17MN/A-1.0830News CoverageOptions VolumeGap DownELDNEledon Pharmaceuticals2.8464 of 5 stars$2.99-2.9%$12.50+318.1%-2.4%$179.05MN/A-1.4910Positive News Related Companies and Tools Related Companies Bright Minds Biosciences Alternatives Innate Pharma Alternatives Cybin Alternatives ProQR Therapeutics Alternatives Lyell Immunopharma Alternatives Voyager Therapeutics Alternatives Nuvectis Pharma Alternatives Organigram Alternatives Ventyx Biosciences Alternatives Eledon Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PEPG) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PEPG Stock Free PEPG Stock Alerts